Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PXS.AU
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Pharmaxis Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 15.17M
- Ent value
- 25.56M
- Price/Sales
- 1.28
- Price/Book
- 4.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -64.41%
- 3 year return
- -37.97%
- 5 year return
- -39.54%
- 10 year return
- -16.66%
Last updated: 2024-12-17
DIVIDENDS
PXS.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.28 |
| Price to Book | 4.30 |
| EV to Sales | 2.15 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 722.61M |
| EPS (TTM) | -0.03 |
| FCF per share (TTM) | -0.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.89M |
| Gross profit (TTM) | 738.00K |
| Operating income (TTM) | -18.82M |
| Net income (TTM) | -18.43M |
| EPS (TTM) | -0.03 |
| EPS (1y forward) | -0.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 6.20% |
| Operating margin (TTM) | -158.20% |
| Profit margin (TTM) | -154.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.14M |
| Net receivables | 856.00K |
| Total current assets | 15.06M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.07M |
| Accounts payable | 2.09M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.09M |
| Total liabilities | 17.54M |
| Shareholder's equity | 3.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.15M |
| Capital expenditures (TTM) | 138.00K |
| Free cash flow (TTM) | -16.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -522.04% |
| Return on Assets | -87.48% |
| Return on Invested Capital | -522.04% |
| Cash Return on Invested Capital | -461.47% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| PXS.AU | S&P500 | |
| Current price drop from All-time high | -99.50% | - |
| Highest price drop | -99.60% | -56.47% |
| Date of highest drop | 29 Jan 2024 | 9 Mar 2009 |
| Avg drop from high | -69.38% | -11.07% |
| Avg time to new high | 60 days | 12 days |
| Max time to new high | 4100 days | 1805 days |
COMPANY DETAILS
Marketcap
15.17M
Marketcap category
Small-cap
Description
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Employees
70
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found